With its launch of a pilot program for the review of novel excipients, the US Food and Drug Administration is generating excitement over what could become a more workable approval pathway than the drug application process.
CDER Pilot Program Offers Potential New Pathway For Approval Of Novel Pharmaceutical Excipients
After decades without an approval pathway for excipients, FDA pilot program paves the way for innovation.
More from Manufacturing
• By
Mechanisms in the draft treaty that the more than 190 member states of the World Health Organization have finally agreed to are expected to “materially affect companies,” particularly those that develop, manufacture or distribute pandemic-related health care products.
• By
The International Council for Harmonisation has consolidated and modernized its existing stability guidelines into one document, and addressed modern stability testing approaches like modeling, bracketing, and matrixing.
• By
Cellares’ fully automated cell therapy manufacturing platform is the first system to receive an Advanced Manufacturing Technology designation from US FDA
• By
The rollout of Trump’s plan has been a policy whiplash, but despite a 90-day pause on tariffs, the US president still appears to be holding a grudge with industry over drug pricing.